Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Urinary Bladder Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Cisplatin Medicine & Life Sciences
Survival Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2017

A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier Cancer Research Network trial HCRN 12-157

Hahn, N. M. , Bivalacqua, T. J. , Ross, A. E. , Netto, G. J. , Baras, A. , Park, J. C. , Chapman, C. , Masterson, T. A. , Koch, M. O. , Bihrle, R. , Foster, R. S. , Gardner, T. A. , Cheng, L. , Jones, D. R. , McElyea, K. , Sandusky, G. E. , Breen, T. , Liu, Z. , Albany, C. , Moore, M. L. & 9 others Loman, R. L., Reed, A., Turner, S. A., De Abreu, F. B., Gallagher, T., Tsongalis, G. J., Plimack, E. R., Greenberg, R. E. & Geynisman, D. M. Jun 15 2017 In : Clinical Cancer Research. 23, 12, p. 3003-3011 9 p.

Research output: Research - peer-reviewArticle

Mycobacterium bovis
Carcinoma
Mutation
Research
Neoplasms

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H. T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., Fishman, M. N., Zhang, J., Srinivas, S., Parikh, J., Antal, J., Jin, X., Gupta, A. K., Ben, Y. & Hahn, N. M. Sep 14 2017 In : JAMA oncology. 3, 9, p. e172411

Research output: Research - peer-reviewArticle

Carcinoma
Safety
Therapeutics
Cell Death
Ligands
Hematuria
Insurance
Databases
Carcinoma
Confidence Intervals

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study

Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., Savage, M. J., Perini, R. F., Keefe, S. M., Bajorin, D. & Bellmunt, J. 2017 (Accepted/In press) In : The Lancet Oncology.

Research output: Research - peer-reviewArticle

Cisplatin
Neoplasms
pembrolizumab
Therapeutics
Drug Therapy

Intravesical BCG Induces CD4+ T-cell expansion in an immune competent model of bladder cancer

Kates, M., Nirschl, T., Sopko, N. A., Matsui, H., Kochel, C. M., Reis, L. O., Netto, G. J., Hoque, M., Hahn, N. M., McConkey, D. J., Baras, A. S., Drake, C. G. & Bivalacqua, T. J. Jul 1 2017 In : Cancer Immunology Research. 5, 7, p. 594-603 10 p.

Research output: Research - peer-reviewArticle

Mycobacterium bovis
Urinary Bladder Neoplasms
T-Lymphocytes
Adaptive Immunity
Urinary Bladder